Transdermal Metformin Overview
February 2026
Metformin hydrochloride is one of the most widely prescribed medications for insulin resistance, type 2 diabetes, polycystic ovary syndrome (PCOS), and obesity-related metabolic dysfunction. While oral metformin remains first-line therapy for many patients, gastrointestinal intolerance—such as nausea, diarrhea, bloating, and abdominal discomfort—frequently limits adherence or leads to discontinuation.
Compounded transdermal metformin HCl cream offers a customized, alternative for select patients who cannot tolerate oral therapy or who require individualized dosing strategies not available in commercially manufactured products.
At Massey Drugs, we compound metformin HCl 50mg per 0.5g pump in a transdermal cream base, prepared for providers seeking an alternative route of administration for metabolic support.
What Is Compounded Transdermal Metformin Cream?
Compounded transdermal metformin is a non–FDA-approved, customized formulation prepared by a licensed compounding pharmacy. Unlike oral immediate or extended-release tablets, this formulation is designed for transdermal absorption, delivering metformin through the skin rather than the gastrointestinal tract.
Because no commercially manufactured transdermal metformin product exists, compounding is required to create this dosage form.
Why Consider a Transdermal Route?
Oral metformin is associated with gastrointestinal side effects in a significant percentage of patients. These effects can occur even at low doses and may persist despite slow titration or use of extended-release formulations.
Transdermal metformin may be considered when:
- Patients experience persistent GI intolerance with oral metformin
- Adherence is compromised due to side effects
- Providers wish to explore alternative delivery routes for metabolic support
- Patients with PCOS or obesity require adjunctive insulin-sensitizing therapy but cannot tolerate oral dosing
By bypassing the gastrointestinal tract, transdermal delivery may reduce systemic GI exposure, potentially improving tolerability in select patients.
Potential Clinical Uses
While transdermal metformin is not FDA-approved for any indication, prescribers may consider it as part of an individualized treatment plan for patients with:
Weight Management and Obesity
Metformin is known to improve insulin sensitivity and reduce hepatic glucose production. Insulin resistance plays a central role in metabolic dysfunction associated with obesity. Transdermal metformin may be explored as an alternative in patients unable to tolerate oral therapy.
Polycystic Ovary Syndrome (PCOS)
Metformin is commonly used off-label in PCOS to address insulin resistance, hyperinsulinemia, and associated metabolic abnormalities. For patients who discontinue oral metformin due to GI side effects, a transdermal option may offer another avenue for metabolic support.
Insulin Resistance and Metabolic Syndrome
Providers managing insulin resistance in non-diabetic patients may consider transdermal metformin as part of a broader lifestyle and pharmacologic strategy when oral formulations are poorly tolerated.
Dosing and Administration
This compounded formulation is dispensed as:
- Metformin HCl 50mg per 0.5g pump
- Transdermal cream in a metered pump for dosing consistency
Typical application sites may include:
- Inner forearm
- Inner thigh
- Alternate low-friction skin areas
Prescribers determine dosing frequency and titration based on clinical judgment and patient response. Typically, transdermal dosing is 10% of oral dosing. Patients should be instructed to apply to clean, dry skin and rotate application sites as directed.
Advantages of Compounded Transdermal Metformin
- Alternative route for patients intolerant to oral metformin
- Customized strength and formulation
- Metered pump for dosing consistency
- Avoids first-pass gastrointestinal exposure
- May improve adherence in select patients
Important Clinical Considerations
- Systemic absorption may vary between patients
- Blood glucose, insulin markers, and metabolic parameters should be monitored as clinically appropriate
- This formulation is not a substitute for lifestyle interventions
- Use should be guided by provider judgment and patient-specific factors
Regulatory and FDA Disclaimer
Compounded medications are not reviewed or approved by the U.S. Food and Drug Administration (FDA) for safety, effectiveness, or quality. Compounded transdermal metformin is prepared based on a valid prescription for an individual patient when an FDA-approved product does not meet that patient’s needs.
Prescriber Support and Compounding Expertise
At Massey Drugs, we work directly with prescribers to compound customized medications that support patient care when commercially available options fall short. If you are evaluating alternative approaches for patients who cannot tolerate oral metformin, compounded transdermal metformin may be a consideration within an individualized treatment plan. Visit the Practitioner Portal weight management section to download our transdermal Metformin prescription blank.
Speak with a Pharmacist
If you have questions about compounded medications our pharmacists are available to consult. Call 833-540-3500 or contact us.